Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) and is notably the only compound in this category with FDA approval — marketed as Egrifta for the reduction of excess visceral fat in…
🔬 Studied for: Visceral Fat Research
💊 Also studied for: GH-Axis Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) and is notably the only compound in this category with FDA approval — marketed as Egrifta for the reduction of excess visceral fat in HIV-associated lipodystrophy.
Tesamorelin binds GHRH receptors in the anterior pituitary, stimulating pulsatile growth hormone release, which in turn raises IGF-1. Its approved clinical effect on visceral adipose tissue is the best-documented outcome among GHRH analogs, supported by Phase 3 clinical trial data.
These are effects Tesamorelin has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
Tesamorelin's approved indication is grounded in clinical trials demonstrating reduced visceral adipose tissue in HIV-associated lipodystrophy, and it remains a reference compound in GHRH-pathway body-composition research.
Beyond its approved use, Tesamorelin is studied more broadly as a tool for examining GHRH receptor pharmacology and downstream GH/IGF-1 signaling in metabolic research.
The FDA-approved clinical dose for Egrifta is 2mg administered by subcutaneous injection once daily, per the product's prescribing information — this reflects the approved clinical protocol, not a recommendation for use of unregulated research material.
Compound X does not provide dosing recommendations. Tesamorelin is sold for laboratory research use only and is not intended for human consumption.
In its FDA-approved clinical use, documented side effects include injection-site reactions, joint pain, swelling, and increased blood glucose; the prescribing information for Egrifta details the full clinical safety profile. Research-grade material sourced outside that regulated supply chain has not undergone the same quality controls.
No. Tesamorelin is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Visceral Fat Research — Tesamorelin's approved indication is grounded in clinical trials demonstrating reduced visceral adipose tissue in HIV-associated lipodystrophy, and it remains a reference compound in GHRH-pathway body-composition research.
In the US, UK, Canada and Australia, Tesamorelin is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
Tesamorelin's clinical trial data and prescribing information are available via the FDA and are also indexed on PubMed under "Tesamorelin GHRH lipodystrophy."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.